Catalyst

Slingshot members are tracking this event:

AbbVie (ABBV) Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ABBV

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 25, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Anti-tau Antibody, Abbv-8e12, Progressive Supranuclear Palsy, Early Alzheimer's Disease